AstraZeneca PLC Files Form 6-K
Ticker: AZN · Form: 6-K · Filed: 2025-08-15T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, foreign-issuer, routine-disclosure
Related Tickers: AZN
TL;DR
AZN filed a 6-K, confirming 20-F reporting. Standard stuff.
AI Summary
AstraZeneca PLC filed a Form 6-K on August 15, 2025, reporting its status as a foreign issuer. The filing confirms that AstraZeneca is submitting its annual reports under Form 20-F. The company is incorporated in the UK with its principal executive offices located in Cambridge.
Why It Matters
This filing is a routine disclosure for foreign issuers, confirming their reporting obligations and providing basic company information to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing for a foreign issuer and does not contain new material financial or operational information.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the Form 6-K
- 0001654954-25-009692 (filing_id) — Accession Number for the filing
- 20250815 (date) — Filing date and period of report
- 001-11960 (commission_file_number) — SEC file number for AstraZeneca PLC
- Form 20-F (document_type) — Annual report form filed by the registrant
- Form 6-K (document_type) — Type of report being filed
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer submitted pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country or to shareholders.
Which annual report form does AstraZeneca PLC file?
AstraZeneca PLC files its annual reports under cover of Form 20-F.
What is AstraZeneca PLC's Central Index Key (CIK)?
AstraZeneca PLC's Central Index Key is 0000901832.
Where are AstraZeneca PLC's principal executive offices located?
AstraZeneca PLC's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
What is the filing date of this Form 6-K?
This Form 6-K was filed on August 15, 2025.
From the Filing
0001654954-25-009692.txt : 20250815 0001654954-25-009692.hdr.sgml : 20250815 20250815104025 ACCESSION NUMBER: 0001654954-25-009692 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250815 FILED AS OF DATE: 20250815 DATE AS OF CHANGE: 20250815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251222935 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a5241v.htm HOLDING(S) IN COMPANY a5241v FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of August 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1.   Holding(s) in Company TR-1: Standard form for notification of major holdings   1. Issuer Details   ISIN GB0009895292   Issuer Name ASTRAZENECA PLC   UK or Non-UK Issuer UK   2. Reason for Notification   An acquisition or disposal of voting rights   3. Details of person subject to the notification obligation   Name The Capital Group Companies, Inc.   City of registered office (if applicable) Los Angeles   Country of registered office (if applicable) USA   4. Details of the shareholder   Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above     City of registered office (if applicable)     Country of registered office (if applicable)     5. Date on which the threshold was crossed or reached   13-Aug-2025   6. Date on which Issuer notified   14-Aug-2025   7. Total positions of person(s) subject to the notification obligation     % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached   5.009591   0.000000   5.009591   77682857   Position of previous notification (if applicable)   4.984560   0.000000   4.984560       8. Notified details of the resulting situation on the date on which the threshold was crossed or reached   8A. Voting rights attached t